Supplemental information (Tables)

3 Months Ended

Nov. 30, 2022

Supplemental Cash Flow Elements [Abstract]

Schedule of Depreciation and Amortization Expense

The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

	Three months ended November 30,
	2022		2021
Depreciation expense	$	336	$	335
Intangible assets amortization	159		165
Total depreciation and amortization expense	$	495	$	500

Restrictions on Cash and Cash Equivalents

The following represents a reconciliation of Cash and cash equivalents in the Consolidated Condensed Balance Sheets to total Cash, cash equivalents, marketable securities and restricted cash in the Consolidated Condensed Statements of Cash Flows as of November 30, 2022 and August 31, 2022, respectively (in millions):

	November 30, 2022		August 31, 2022
Cash and cash equivalents	$	2,349	$	1,358
Marketable securities	1,883		1,114
Restricted cash - (included in other current assets)	82		86
Cash, cash equivalents, marketable securities and restricted cash	$	4,314	$	2,558

Schedule of Redeemable Noncontrolling Interest

The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):

	Three months ended November 30,
	2022		2021
Opening balance	$	1,042	$	319
Acquisition of non-controlling interests 1	—		2,489
Net loss attributable to Redeemable non-controlling interests	(22)		(21)
Redemption price adjustments 2	440		7
Reclassifications to Accrued expenses and other liabilities 3	(1,314)		—
Other	12		(8)
Ending balance	$	157	$	2,787

1.The three months ended November 30, 2021 includes $1.9 billion of redeemable non-controlling interest representing the maximum purchase price to redeem non-controlling units in VillageMD for cash. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 24, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.

2.Remeasurement of non-controlling interests, probable of redemption but not currently redeemable, to their redemption value, is recorded to Paid in capital in the Consolidated Condensed Balance Sheets. During the three months ended November 30, 2022, the Company announced the acceleration of its plans for full ownership of Shields and CareCentrix. The Shields and CareCentrix redeemable non-controlling interests were recorded to redemption value.

3.Represents the reclassification of the Shields and CareCentrix redeemable non-controlling interests resulting from acceleration of the Company's plans for full ownership of Shields and CareCentrix.

See Note 2. Acquisitions and other investments for further information.

Schedule of Dividends Payable

Cash dividends per common share declared were as follows:

Quarter ended	2022		2021
November	$	0.4800	$	0.4775